Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
William W. Busse(UW Health University Hospital), Christine A. Sorkness(University of Wisconsin–Madison), Suzanne Steinbach(Boston University), Stanley J. Szefler(National Jewish Health), Katherine M. Thompson(National Institute of Allergy and Infectious Diseases), Meyer Kattan(Icahn School of Medicine at Mount Sinai), James F. Chmiel(Indiana University School of Medicine), Jacqueline A. Pongracic(Lurie Children's Hospital), Rebecca S. Gruchalla(The University of Texas Southwestern Medical Center), Alkis Togias, Stephen J. Teach(Children's National), Peter J. Gergen(National Institute of Allergy and Infectious Diseases), Wayne J. Morgan(University of Arizona), Andrew H. Liu(National Jewish Health), Agustin Calatroni(Johns Hopkins University), Herman Mitchell(Rho (United States)), James E. Gern(University of Wisconsin–Madison)
Cited by 870
Related Papers
Asthma and Wheezing in the First Six Years of Life
|New England Journal of Medicine|1995|3.8k
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
|Journal of Allergy and Clinical Immunology|2006|2.3k
Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
|The Lancet|1999|1.6k
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
|Journal of Allergy and Clinical Immunology|2001|1.3k